Embecta Corp. (NASDAQ: EMBC) announced that Nimish Muzumdar has been appointed Senior Vice President and President, North America, effective June 15, 2026, according to a company press release.

Muzumdar will oversee the company's commercial teams in the United States and Canada and will report to Dev Kurdikar, Chairman, President and CEO. He will also serve on the embecta Operating Team.

Muzumdar previously served as Senior Vice President and Head of Generics at Sandoz, where he led a division with $1 billion in revenue. He joined Sandoz following its spinoff from Novartis in 2023 and held multiple roles at the company over more than a decade, including positions focused on oncology, injectables, and retail generics. Before Sandoz, he held marketing roles at Ranbaxy USA, Watson Laboratories, and Dr. Reddy's Laboratories.

Muzumdar holds a Bachelor of Science in Pharmacy from the University of Mumbai and an MBA from the New York Institute of Technology.

As an inducement grant tied to his employment, Muzumdar received 638,978 time-vested restricted stock units. The units will vest 20% on the first anniversary of the grant date, 50% on the second anniversary, and 30% on the third anniversary, subject to continued employment. The award was approved by embecta's Board of Directors under Nasdaq Listing Rule 5635(c)(4).